U24CA274496

Management and Data Coordination Unit for PCDC - Project Summary

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, partially owing to lack of effective biomarkers and/or screening strategies. The 5-year survival of patients with localized PDAC is 39% compared to 3% in patients diagnosed with metastatic disease, which indicates that detecting PDAC at early stage positively impacts survival.

A centrally curated/managed multi-institution biospecimen resource containing prospectively collected, well-annotated biospecimens representing clinically relevant, diverse PDAC screening populations is desperately needed.

The overall goal of the Pancreatic Cancer Detection Consortium (PCDC) Management and Data Coordinating Center (MDCU) is to facilitate the PCDC's role in developing and utilizing high quality, well annotated samples for PDAC biomarker discovery, triage, pre-validation, and validation.

The PCDC consortium is composed of multiple U01 research units (RU) and the MDCU, with NCI cooperation and central biospecimen storage at the NCI Frederick Central Repository.

We will leverage our expertise and knowledge gained during the previous grant cycle to reinforce existing and new PCDC initiatives through expanded coordination, and strengthening the infrastructure to support management of the PCDC reference sets and signature protocols.

Our specific aims are:
1) To provide outstanding and timely administrative coordination and logistical support for the Pancreatic Cancer Detection Consortium.
2) To strategically plan, coordinate and implement the development of a well-annotated, uniformly collected and managed central PCDC biorepository and database.
3) To provide the highest quality biostatistical leadership of PCDC collaborative experimental design, study conduct, and analysis, and to provide biostatistical consultation to PCDC RUs.

The strengths of the MDCU are the breadth and depth of knowledge and understanding of PDAC provided by MDCU personnel who will innovatively apply time-tested infrastructure tools and strategies to consortium management, and our vast experience in enhancing the scientific needs of PCDC collaborative research.

Our multidisciplinary team is committed to continue its leadership and contribution to the PCDC organization to advance the early detection of pancreatic cancer.

Mayo Clinic

TO IMPROVE SCREENING AND EARLY DETECTION STRATEGIES AND TO DEVELOP ACCURATE DIAGNOSTIC TECHNIQUES AND METHODS FOR PREDICTING THE COURSE OF DISEASE IN CANCER PATIENTS. SCREENING AND EARLY DETECTION RESEARCH INCLUDES DEVELOPMENT OF STRATEGIES TO DECREASE CANCER MORTALITY BY FINDING TUMORS EARLY WHEN THEY ARE MORE AMENABLE TO TREATMENT. DIAGNOSIS RESEARCH FOCUSES ON METHODS TO DETERMINE THE PRESENCE OF A SPECIFIC TYPE OF CANCER, TO PREDICT ITS COURSE AND RESPONSE TO THERAPY, BOTH A PARTICULAR THERAPY OR A CLASS OF AGENTS, AND TO MONITOR THE EFFECT OF THE THERAPY AND THE APPEARANCE OF DISEASE RECURRENCE. THESE METHODS INCLUDE DIAGNOSTIC IMAGING AND DIRECT ANALYSES OF SPECIMENS FROM TUMOR OR OTHER TISSUES. SUPPORT IS ALSO PROVIDED FOR ESTABLISHING AND MAINTAINING RESOURCES OF HUMAN TISSUE TO FACILITATE RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.394 - Cancer Detection and Diagnosis Research

National Cancer Institute (NCI) [HHS - NIH]

Rochester, Minnesota 559050001 United States

Single Zip Code

Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) (PAR-21-335)

Amendment Since initial award the total obligations have increased 293% from $659,848 to $2,593,209.